The Current Landscape of Molecular Pathology for the Diagnosis and Treatment of Pediatric Medulloblastoma
Medulloblastoma (MB) is a malignant brain tumor that requires intense multimodal treatment. There is significant treatment-related morbidity associated with MB, and overall prognosis varies between the subgroups of the disease. These tumors were previously risk-stratified based solely on histopathol...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Journal of Molecular Pathology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-5261/6/2/11 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839653660877914112 |
|---|---|
| author | Alayna Koch Ashley Childress Emma Vallee Alyssa Steller Scott Raskin |
| author_facet | Alayna Koch Ashley Childress Emma Vallee Alyssa Steller Scott Raskin |
| author_sort | Alayna Koch |
| collection | DOAJ |
| description | Medulloblastoma (MB) is a malignant brain tumor that requires intense multimodal treatment. There is significant treatment-related morbidity associated with MB, and overall prognosis varies between the subgroups of the disease. These tumors were previously risk-stratified based solely on histopathological features. However, advancements in oncologic molecular research have led to novel changes to MB tumor classification, which also affects the prognosis and treatment strategies for individual patients. The WHO CNS5 now recognizes four main molecular subgroups of MB. Each subgroup contains its own genomic heterogeneity that correlates with a unique way to risk stratify patients, determine overall prognosis, and inform treatment. These discoveries have already impacted the implications and outcomes of current treatments based on the subgroup of patients. Ongoing research to better understand this classification system has paved the way for the development of molecular targeted therapy. |
| format | Article |
| id | doaj-art-4c58aec7d56542f2b85af3272a8c46c8 |
| institution | Matheson Library |
| issn | 2673-5261 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Molecular Pathology |
| spelling | doaj-art-4c58aec7d56542f2b85af3272a8c46c82025-06-25T14:01:00ZengMDPI AGJournal of Molecular Pathology2673-52612025-06-01621110.3390/jmp6020011The Current Landscape of Molecular Pathology for the Diagnosis and Treatment of Pediatric MedulloblastomaAlayna Koch0Ashley Childress1Emma Vallee2Alyssa Steller3Scott Raskin4Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229-3039, USADepartment of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229-3039, USADepartment of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229-3039, USADepartment of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229-3039, USADepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45229-3039, USAMedulloblastoma (MB) is a malignant brain tumor that requires intense multimodal treatment. There is significant treatment-related morbidity associated with MB, and overall prognosis varies between the subgroups of the disease. These tumors were previously risk-stratified based solely on histopathological features. However, advancements in oncologic molecular research have led to novel changes to MB tumor classification, which also affects the prognosis and treatment strategies for individual patients. The WHO CNS5 now recognizes four main molecular subgroups of MB. Each subgroup contains its own genomic heterogeneity that correlates with a unique way to risk stratify patients, determine overall prognosis, and inform treatment. These discoveries have already impacted the implications and outcomes of current treatments based on the subgroup of patients. Ongoing research to better understand this classification system has paved the way for the development of molecular targeted therapy.https://www.mdpi.com/2673-5261/6/2/11medulloblastoma (MB)molecular pathologymethylation profilingwingless (WNT)sonic hedgehog (SHH)group 3 |
| spellingShingle | Alayna Koch Ashley Childress Emma Vallee Alyssa Steller Scott Raskin The Current Landscape of Molecular Pathology for the Diagnosis and Treatment of Pediatric Medulloblastoma Journal of Molecular Pathology medulloblastoma (MB) molecular pathology methylation profiling wingless (WNT) sonic hedgehog (SHH) group 3 |
| title | The Current Landscape of Molecular Pathology for the Diagnosis and Treatment of Pediatric Medulloblastoma |
| title_full | The Current Landscape of Molecular Pathology for the Diagnosis and Treatment of Pediatric Medulloblastoma |
| title_fullStr | The Current Landscape of Molecular Pathology for the Diagnosis and Treatment of Pediatric Medulloblastoma |
| title_full_unstemmed | The Current Landscape of Molecular Pathology for the Diagnosis and Treatment of Pediatric Medulloblastoma |
| title_short | The Current Landscape of Molecular Pathology for the Diagnosis and Treatment of Pediatric Medulloblastoma |
| title_sort | current landscape of molecular pathology for the diagnosis and treatment of pediatric medulloblastoma |
| topic | medulloblastoma (MB) molecular pathology methylation profiling wingless (WNT) sonic hedgehog (SHH) group 3 |
| url | https://www.mdpi.com/2673-5261/6/2/11 |
| work_keys_str_mv | AT alaynakoch thecurrentlandscapeofmolecularpathologyforthediagnosisandtreatmentofpediatricmedulloblastoma AT ashleychildress thecurrentlandscapeofmolecularpathologyforthediagnosisandtreatmentofpediatricmedulloblastoma AT emmavallee thecurrentlandscapeofmolecularpathologyforthediagnosisandtreatmentofpediatricmedulloblastoma AT alyssasteller thecurrentlandscapeofmolecularpathologyforthediagnosisandtreatmentofpediatricmedulloblastoma AT scottraskin thecurrentlandscapeofmolecularpathologyforthediagnosisandtreatmentofpediatricmedulloblastoma AT alaynakoch currentlandscapeofmolecularpathologyforthediagnosisandtreatmentofpediatricmedulloblastoma AT ashleychildress currentlandscapeofmolecularpathologyforthediagnosisandtreatmentofpediatricmedulloblastoma AT emmavallee currentlandscapeofmolecularpathologyforthediagnosisandtreatmentofpediatricmedulloblastoma AT alyssasteller currentlandscapeofmolecularpathologyforthediagnosisandtreatmentofpediatricmedulloblastoma AT scottraskin currentlandscapeofmolecularpathologyforthediagnosisandtreatmentofpediatricmedulloblastoma |